I attended
the day-long Clinical Practice update session of this event as the Consumer
Lead on the ACT Standard 7 Blood and Blood Products Committee. HCCA sponsored my registration.
Most
presentations were very well received and focused on projects or programs
designed to help health services develop their Transfusion Quality Improvement
Systems so that they comply with Standard 7 which requires;
“Clinical leaders and senior managers
of a health service organisation implement systems to ensure the safe,
appropriate, efficient and effective use of blood and blood products.
Clinicians and other members of the workforce use the blood and blood product
safety systems.”
and on the
accreditation criteria listed at the bottom of the post.*
Both the
Australian Red Cross Blood Service and the National Blood Authority have developed
of smart phone/IPad applications (apps) to provide information and support for
transfusion services. A WA Red Cross Blood Service app designed for services
treating people with high iron/ferritin levels was reported as achieving
reduced times from referral to treatment and cost savings for health services. High iron and related conditions are
apparently becoming more common because people are living longer and are more
readily diagnosed.
Through the NBA app transfusion
service can access information about:
1. Use and management of blood and
blood products in accordance with national evidence-based guidelines.
2. Risk mitigation, education and
safety and quality improvement programs for the management and use of blood and
blood products.
3. Reporting and feedback mechanisms
into risk management processes for adverse events, incidents and near misses
relating to transfusion practice.
4. Policies, procedures and protocols
for documenting transfusion details in the patient clinical record.
5.
Appropriate management of blood and blood products.
6. Informed consent is documented for
transfusions.
From my point of view development of smart technology apps will provide a new level of immediate access to evidence based information and therefore should reduce delays in determining the best approach to treatment. The alternative up until now (when beside computers were not available) was access to information via a desktop.
A
presentation on informed consent revealed that there is no agreed approach to
obtaining consent in terms of blood and blood products. Some services get separate consent for each
type of blood product; some services appear to use the general consent signed
on admission to hospital as consent for blood and blood products; and some
presenters suggested their organisation is considering getting separate consent
for each unit of blood or blood product given to a consumer.
My impression was that there is good
communication between the NBA and State Based Transfusion Services and between
individual State and Territory services.
Participants did say that they valued
the opportunity to network and develop links with other services and individual
clinicians.
Jo Bothroyd
*Standard 7 four key Accreditation
Criteria
Governance and systems for
blood and blood products prescribing and clinical use - Health service organisations have
systems in place for the safe and appropriate prescribing and clinical use of
blood and blood products.
Documenting patient
information
- The clinical workforce accurately records a patient’s blood and blood
product transfusion history and indications for use of blood and blood
products.
Managing blood and blood
product safety
- Health service organisations have systems in place to receive, store,
transport and monitor wastage of blood and blood products safely and
efficiently.
Communicating with
patients and carers
- Patients and carers are informed about the risks and benefits of using
blood and blood products, and the available alternatives when a plan for
treatment is developed.
